Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from SSY Group ( (HK:2005) ) is now available.
SSY Group Limited has announced that it received approval from the National Medical Products Administration of China for the production and registration of Tolterodine Tartrate Sustained-release Capsules, a treatment for overactive bladder. This approval marks the third such recognition for SSY Group among PRC entities, potentially enhancing its market position and offering new opportunities for growth in the pharmaceutical sector.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of chemical drugs. The company is involved in creating products that address various medical needs, with a particular emphasis on drug production and registration in China.
Average Trading Volume: 14,001,176
Technical Sentiment Signal: Sell
Current Market Cap: HK$9.09B
Learn more about 2005 stock on TipRanks’ Stock Analysis page.